ASH 2023: Roche's Columvi and Lunsumio shows continued benefit for people with lymphoma

Swiss pharma giant Roche (ROG: SIX) has presented new data from its CD20xCD3 T-cell engaging bispecific antibody program at the 65th American Society of Hematology (ASH) Annual Meeting.

Based on 32-month and three-year follow-ups of two pivotal studies for fixed-duration treatments of Columvi (glofitamab) and Lunsumio (mosunetuzumab), respectively, data show that remissions were maintained in the majority of patients with heavily pre-treated lymphomas. Additionally, new early-phase data of novel Columvi or Lunsumio (both separately already approved in the USA) combination regimens support ongoing investigation in Phase III studies in earlier lines of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

“Updated data from pivotal studies of Columvi and Lunsumio continue to provide compelling evidence for how fixed-duration therapies can deliver sustained, long-term benefit for people with difficult-to-treat lymphomas,” said Dr Levi Garraway, Roche’s chief medical officer and head of global product development. “Our data at ASH also demonstrate progress in evaluating our bispecific antibodies in earlier stages of disease and additional types of lymphoma so more people can benefit from our therapies,” he noted.